The continued deterioration of natural gas prices may result in the fulcrum moving to the unsecured bonds from the preferred shares.
Just in from Seeking Alpha at Google
Member since: Oct 27, 2015
Nothing but a Short with a new Alias ID in Sheep's clothing, not to mention a Numb Nuts.
October 20, 2015 Analyst News
Inuvo Inc Receives a Buy from Roth Capital
By George Macdonald
Roth Capital analyst William Gibson maintained a Buy rating on Inuvo Inc (NYSE MKT: INUV) today and set a price target of $4.50. The company’s shares opened today at $2.78.
Gibson noted, “earnings increase 50% per share to $0.03 from $0.02 on an estimated 31% improvement in revenue to $17 million from $13 million. We expect growth at the company’s own sites as well that the thousands of online publishers in its partner network, each accentuated by SearchLinks native-style, mobile-friendly advertisements that match content. Inuvo operates a scalable, end-to-end digital advertising platform delivering billions of ads monthly .”
Inuvo Inc has an analyst consensus of Moderate Buy.
Based on Inuvo Inc`s latest earnings report from June 30, the company posted quarterly revenue of $16.73M and quarterly net profit of $445k. In comparison, last year the company earned revenue of $13.03M and had a net profit of $402.9k.
Like Roth Capital`s latest rating, based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INUV in relation to earlier this year. Last month, William Conner, a a Director at INUV bought 29,400 shares for a total of $74,382.
Gibson is ranked 0 out of 5 stars with an average return of -22.4% and a 7.1% success rate. Gibson covers the Services sector, focusing on stocks such as Marathon Patent Group, NTN Buzztime, and RMG Networks.
Inuvo Inc is an internet marketing and technology company. It delivers purchase-ready customers to advertisers through a network of websites and applications reaching both desktop and mobile devices.
What catches my attention is: Roche is counting on new products to offset generic competition to its aging cancer blockbusters.
I think that a buyout of the Exelixis by Roche is possible, considering the comments by the Roche CEO from yesterday. How stockholders will benefit remains to be seen, mostly with the timing of such an event and whether the stock has increased in price sufficiently to attain a premium. There are many who would prefer to see the company stand alone and make a run on its own at becoming a larger company.
The company could buy back most of its preferred shares at a premium to their current prices and at a considerable discount to par.
Hillary has been invested in a hedge fund that shorts biotechnology company stocks and that is a fact.
I am not sure why you are wasting time here considering that you should be writing scripts for television instead of continually spinning your preposterous yarns.
fillup_cheap, I appreciate your response and I thank you.
bwhitc2015 : Member since: Oct 12, 2015, being today.
You are seriously busted, new Alias ID Shortie.
The company seems to have a lot of subsidiaries and own a lot of land. Does MHR own Green Hunter Resources GRH with Gary who is the CEO?